James Brown
Optometrist · Lagrange, GANPI 1679626543
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $363 of the $481 with a category attached, or 75.5%. 9 manufacturers reported payments, led by Alcon at 27.8% of the total. Reporting peaked in 2019 at $174 and has fallen 65.6% since, to $60 in 2025. That places this record below the midpoint for optometrist clinicians in GA, where the typical reported total is $813.
Across 20 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$134
- Optos, Inc.$118
- Coopervision Inc.$100
- Dompe US, Inc.$36
- AbbVie$25
- Bausch & Lomb Americas Inc.$22
- plus $46 from 3 others
What the payments were for
- Food & beverage$36375%
- Entertainment$11825%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 7 | $134 |
| Optos, Inc. | 1 | $118 |
| Coopervision Inc. | 6 | $100 |
| Dompe US, Inc. | 1 | $36 |
| AbbVie | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Maculogix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$481 in reported general payments places this provider in the 35th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 81 | $1,042 |
| Brimonidine Tartrate | 23 | $992 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $257 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $176 |
| Timolol Maleate | 24 | $103 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Lagrange
- Joshua JohnstonAtlanta$993K
- John WomackCanton$931K
- Naheed AhmadRoswell$296K
- Scott MoscowRoswell$278K
- Stephen SummerowPerry$222K
- Janelle DavisonSmyrna$199K
- Keyle BrownDawsonville$182K
- Nacondus GambleFort Stewart$175K
- Amber ZaunbrecherAtlanta$99K
- Jeffrey CofieWarner Robins$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.